Givosiran - Alnylam Pharmaceuticals

Drug Profile

Givosiran - Alnylam Pharmaceuticals

Alternative Names: ALN-AS1

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute intermittent porphyria

Most Recent Events

  • 07 Nov 2017 Phase-III clinical trials in Acute intermittent porphyria (In adolescents, In the elderly, In adults) in USA (SC) (NCT03338816)
  • 07 Sep 2017 Alnylam announces intention to submit NDA to the US FDA for Acute intermittent porphyria at the end of 2018
  • 07 Sep 2017 Adverse events and efficacy data from a phase I trial in Acute intermittent porphyria released by Alnylam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top